Why aren't physicians prescribing more buprenorphine?
Why aren't physicians prescribing more buprenorphine?
复制标题
DOI：
10.1016/j.jsat.2017.04.005
复制
发表时间：
2017-07-01
影响因子：
3.9
通讯作者：
Dunn, Kelly E.
中科院分区：
文献类型：
--
作者：
Huhn, Andrew S.;Dunn, Kelly E.
背景与目的：丁丙诺啡是一种未被充分利用的药物，在抗击阿片类药物流行中起着关键作用。患有阿片类药物使用障碍(OUD)的人经常很难找到开丁丙诺啡处方的医生。许多医生没有处方丁丙诺啡的豁免权，而且被豁免的医生中有很大一部分没有按能力开处方。本研究旨在定量了解为什么医生没有更频繁地使用丁丙诺啡治疗尿毒症。方法：对558名有和没有丁丙诺啡豁免处方的医生进行了调查，了解他们认为丁丙诺啡处方存在的缺陷。此外，已确定资源，鼓励未获豁免的病人获得豁免，而获豁免的病人则接受更多新病人。这项调查于2016年春/夏通过美国成瘾医学会和美国医学会列表在线分发给医生。结果和结论：采用Logistic回归分析找出受访者表示不愿增加处方的原因(X-2(4)=73.18，p
Background & objective: Buprenorphine is an underutilized pharmacotherapy that can play a key role in combating the opioid epidemic. Individuals with opioid use disorder (OUD) often struggle to find physicians that prescribe buprenorphine. Many physicians do not have the waiver to prescribe buprenorphine, and a large proportion of physicians that are waivered do not prescribe to capacity. This study aimed to quantitatively understand why physicians do not utilize buprenorphine for the treatment of OUD more frequently.Methods: Physicians (n = 558) with and without the waiver to prescribe buprenorphine were surveyed about perceived drawbacks associated with prescribing buprenorphine. Furthermore, resources were identified that would encourage those without the waiver to obtain it, and those with the waiver to accept more new patients. The survey was distributed online to physicians in the spring/summer of 2016 via the American Society for Addiction Medicine and American Medical Association listservs.Results and conclusions: A logistic regression analysis was used to identify reasons that respondents indicated no willingness to increase prescribing (X-2(4) = 73.18,p